Log in

Relevant bibliographies by topics / Leukemia and Lymphoma / Journal articles

To see the other types of publications on this topic, follow the link: Leukemia and Lymphoma.

Journal articles on the topic 'Leukemia and Lymphoma'

Author: Grafiati

Published: 5 June 2025

Last updated: 2 August 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Leukemia and Lymphoma.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Edlefsen, Kerstin Lara, Anneclaire De Roos, and Andrea LaCroix. "Application of the InterLymph Consortium’s Proposed Classification of Lymphoid Neoplasms for Epidemiologic Research to a Large, Nationwide Health Study: Experience in the Women’s Health Initiative." Blood 112, no. 11 (2008): 4669. http://dx.doi.org/10.1182/blood.v112.11.4669.4669.

Full text

Abstract:

Abstract Large cohort studies, such as the Women’s Health Initiative, have traditionally grouped hematopoietic neoplasms (HPN) into disease categories including multiple myeloma (MM), non-Hodgkin lymphoma (NHL), Hodgkin lymphoma (HL), and leukemia, however this may not allow for optimal distinction of biologically relevant associations. The 2001 World Health Organization (WHO) classification of HPN represents the current gold standard classification scheme, and has been incorporated into the International Classification of Disease for Oncology, Third Edition (ICD-O-3). In 2007, the Internation

APA, Harvard, Vancouver, ISO, and other styles

2

Wang, Wei, Magdalena Czader, and Sa A. Wang. "Blood- and bone marrow–based mature T-cell and natural killer cell leukemias and lymphomas: a summary in the series of the 2023 SH/EAHP Workshop." American Journal of Clinical Pathology 164, no. 1 (2025): 7–25. https://doi.org/10.1093/ajcp/aqaf009.

Full text

Abstract:

Abstract This session included 51 cases submitted to the workshop “Progress in T- and NK-cell Lymphomas and Leukemias” by the Society for Hematopathology and European Association for Haematopathology under “Blood/Bone Marrow–Based Mature T- and NK-Cell Leukemias/Lymphomas” or “T/NK-cell neoplasms with a Leukemic Presentation.” Entities encompassed T-cell prolymphocytic leukemia, T-cell large granular lymphocytic leukemia (LGLL), natural killer (NK)-LGLL/chronic lymphoproliferative disorder of NK cells, adult T-cell leukemia/lymphoma, aggressive NK-cell leukemia, and their mimics. Submitted cas

APA, Harvard, Vancouver, ISO, and other styles

3

Rodig, Scott J., Jeremy S. Abramson, Geraldine S. Pinkus, Steven P. Treon, Margaret A. Shipp, and Jeffery L. Kutok. "Evaluation of CD52 Expression in Hematopoietic Neoplasms by Standard Immunohistochemistry: Implications for the Expanded Use of Alemtuzumab (CAMPATH-1H) in the Treatment of Hematological Malignancies." Blood 106, no. 11 (2005): 3346. http://dx.doi.org/10.1182/blood.v106.11.3346.3346.

Full text

Abstract:

Abstract CD52 is a GPI-linked glycoprotein expressed by B cells, T cells, monocytes and macrophages. The humanized monoclonal antibody alemtuzumab (CAMPATH-1H) is specific for CD52 and is FDA-approved for the treatment of relapsed or refractory chronic lymphocytic leukemia (CLL). The utility of alemtuzumab in the treatment of other lymphoid and non-lymphoid malignancies has been recently explored; however, a comprehensive survey of CD52 expression among the various classes of hematopoietic neoplasms has not been completed. In addition, most methods of detecting CD52 rely on flow cytometric tec

APA, Harvard, Vancouver, ISO, and other styles

4

Shi, Yang, and Endi Wang. "Blastic Plasmacytoid Dendritic Cell Neoplasm: A Clinicopathologic Review." Archives of Pathology & Laboratory Medicine 138, no. 4 (2014): 564–69. http://dx.doi.org/10.5858/arpa.2013-0101-rs.

Full text

Abstract:

Blastic plasmacytoid dendritic cell neoplasm is a rare entity grouped with the acute myeloid leukemia–related precursor neoplasms in the 2008 World Health Organization classification. It was previously postulated to originate from natural killer cells, T cells, or monocytes but is now believed to arise from the plasmacytoid dendritic cell. The pathogenesis of blastic plasmacytoid dendritic cell neoplasm is not well understood, although the neoplasm demonstrates frequent deletion of tumor suppressor genes, including RB1, CDKN1B, CDKN2A, and TP53. Blastic plasmacytoid dendritic cell neoplasm is

APA, Harvard, Vancouver, ISO, and other styles

5

Dunphy, Cherie H. "Gene Expression Profiling Data in Lymphoma and Leukemia: Review of the Literature and Extrapolation of Pertinent Clinical Applications." Archives of Pathology & Laboratory Medicine 130, no. 4 (2006): 483–520. http://dx.doi.org/10.5858/2006-130-483-gepdil.

Full text

Abstract:

Abstract Context.—Gene expression (GE) analyses using microarrays have become an important part of biomedical and clinical research in hematolymphoid malignancies. However, the methods are time-consuming and costly for routine clinical practice. Objectives.—To review the literature regarding GE data that may provide important information regarding pathogenesis and that may be extrapolated for use in diagnosing and prognosticating lymphomas and leukemias; to present GE findings in Hodgkin and non-Hodgkin lymphomas, acute leukemias, and chronic myeloid leukemia in detail; and to summarize the pr

APA, Harvard, Vancouver, ISO, and other styles

6

Pals, S. T., M. Zijstra, T. Radaszkiewicz, et al. "Immunologic induction of malignant lymphoma: graft-vs-host reaction-induced B cell lymphomas contain integrations of predominantly ecotropic murine leukemia proviruses." Journal of Immunology 136, no. 1 (1986): 331–39. http://dx.doi.org/10.4049/jimmunol.136.1.331.

Full text

Abstract:

Abstract The induction of a graft-vs-host reaction in (BALB/c X A)F1 mice by i.v. injection with BALB/c lymphoid cells leads to a lymphoid hyperplasia that may progress to malignant lymphoma. In the present paper, the following aspects of graft-vs-host-reaction lymphomagenesis were studied: 1) the cellular requirements for the induction of lymphomas, 2) their cellular origin, and 3) the role of murine leukemia viruses. The development of graft-vs-host-reaction lymphomas was found to be mediated by donor T cells and to require the presence of histoincompatibility between donor and host. Histolo

APA, Harvard, Vancouver, ISO, and other styles

7

Rateesh, Sareen, Garima Agarwal, and Gajendra Nath Gupta. "Lymphoglandular bodies as useful morphological clue in diagnosis of Lymphoid malignancies- A Case Report." International Journal of Clinicopathological Correlation 8, no. 1 (2024): 12–16. http://dx.doi.org/10.56501/intjclinicopatholcorrel.v8i1.1036.

Full text

Abstract:

Lymphoglandular bodies, observed as round basophilic cytoplasmic fragments on Giemsa stain, are linked with lymphoid malignancies, aiding in distinguishing lymphomas from other small round cell tumors. This case report underscores the diagnostic significance of Lymphoglandular bodies in Acute lymphoid leukemia diagnosis through bone marrow biopsy. We present a case of a 21-year-old male with chest pain and weakness. The bone marrow biopsy revealed a monomorphic cell population with a high nuclear cytoplasmic ratio, prompting immunomarker analysis that confirmed the presence of blasts as lympho

APA, Harvard, Vancouver, ISO, and other styles

8

Longe, Harold, Douglas V. Faller, and Gerald V. Denis. "Telomere-Based Pre-Clinical Therapy in a Murine Model of Non-Hodgkin’s Lymphoma of the Diffuse Large B Cell (DLCL)Type." Blood 106, no. 11 (2005): 607. http://dx.doi.org/10.1182/blood.v106.11.607.607.

Full text

Abstract:

Abstract The dual bromodomain Brd2 is closely related to the basal transcription factor TAFII250, which is essential for cyclin A transactivation and mammalian cell cycle progression. Constitutive expression of BRD2 (under Eμ control) in the lymphoid lineage of transgenic mice elevates basal transcription of cyclin A, destabilizes the cell cycle and leads to B cell leukemias and lymphomas that are monoclonal, morphologically uniform, transplantable and highly malignant. The surface immunophenotype of the lymphoma cells is: B220+, CD19+, sIgM+, CD5+, CD9+; B7-1 and B7-2 elevated, CD23low; CD11b

APA, Harvard, Vancouver, ISO, and other styles

9

Taylor, Justin, Wenbin Xiao, and Omar Abdel-Wahab. "Diagnosis and classification of hematologic malignancies on the basis of genetics." Blood 130, no. 4 (2017): 410–23. http://dx.doi.org/10.1182/blood-2017-02-734541.

Full text

Abstract:

Abstract Genomic analysis has greatly influenced the diagnosis and clinical management of patients affected by diverse forms of hematologic malignancies. Here, we review how genetic alterations define subclasses of patients with acute leukemias, myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPNs), non-Hodgkin lymphomas, and classical Hodgkin lymphoma. These include new subtypes of acute myeloid leukemia defined by mutations in RUNX1 or BCR-ABL1 translocations as well as a constellation of somatic structural DNA alterations in acute lymphoblastic leukemia. Among patients with M

APA, Harvard, Vancouver, ISO, and other styles

10

Ginsberg, AM, M. Raffeld, and J. Cossman. "Inactivation of the retinoblastoma gene in human lymphoid neoplasms." Blood 77, no. 4 (1991): 833–40. http://dx.doi.org/10.1182/blood.v77.4.833.833.

Full text

Abstract:

Abstract The absence of wild type retinoblastoma (Rb) gene expression in a wide variety of human solid tumors suggests an etiologic role for this tumor suppressor gene in human cancer. We have evaluated the involvement of Rb gene inactivation in the pathogenesis and progression of human lymphoma and leukemia. We examined the genomic configuration and transcription of the Rb gene in cultured cell lines and primary cases of T- and B-cell lymphomas and leukemias. By Southern analysis, abnormalities of the Rb locus were identified in 1 of 5 T-cell acute lymphoblastic lymphoma (T-ALL) cell lines, 1

APA, Harvard, Vancouver, ISO, and other styles

11

Ginsberg, AM, M. Raffeld, and J. Cossman. "Inactivation of the retinoblastoma gene in human lymphoid neoplasms." Blood 77, no. 4 (1991): 833–40. http://dx.doi.org/10.1182/blood.v77.4.833.bloodjournal774833.

Full text

Abstract:

The absence of wild type retinoblastoma (Rb) gene expression in a wide variety of human solid tumors suggests an etiologic role for this tumor suppressor gene in human cancer. We have evaluated the involvement of Rb gene inactivation in the pathogenesis and progression of human lymphoma and leukemia. We examined the genomic configuration and transcription of the Rb gene in cultured cell lines and primary cases of T- and B-cell lymphomas and leukemias. By Southern analysis, abnormalities of the Rb locus were identified in 1 of 5 T-cell acute lymphoblastic lymphoma (T-ALL) cell lines, 1 of 26 pr

APA, Harvard, Vancouver, ISO, and other styles

12

Tagawa, Hiroyuki, Yasuo Yamanaka, Atsushi Watanabe, Naoto Takahashi, and Ken-ichi Sawada. "Aberrant Overexpressions of MicroRNA-21 and MicroRNA-155 Activate AKT Signaling Via Downregulation of Tumor Suppressors in NK-Cell Lymphoma/Leukemia." Blood 114, no. 22 (2009): 1917. http://dx.doi.org/10.1182/blood.v114.22.1917.1917.

Full text

Abstract:

Abstract Abstract 1917 Poster Board I-940 Background: Natural Killer (NK) cell lymphomas/leukemias are characterized groups of highly aggressive lymphoid malignancies, which are comprised of “extranodal NK/T cell lymphoma, nasal type” and “aggressive NK-cell leukemia”. Notably, these two subtypes show many similarities in their morphologic features, immmunophenotypes and genotypes, and are invariably associated with Epstein-Barr virus (EBV), which suggests they may share the same genetic alterations. The gene(s) responsible for natural killer (NK)-cell lymphoma/leukemia have not been identifie

APA, Harvard, Vancouver, ISO, and other styles

13

Tomacinschii, Victor, Maria Robu, Vasile Musteață, et al. "SECONDARY ACUTE PROMYELOCYTIC LEUKEMIA DEVELOPED AFTER TREATMENT OF NON-HODGKIN'S LYMPHOMA. CLINICAL CASE AND REVIEW OF LITERATURE." Arta Medica 76, no. 3 (2020): 115–18. https://doi.org/10.5281/zenodo.4070160.

Full text

Abstract:

<strong>Background. </strong>Acute promyelocytic leukemia is an acute myeloid leukemia that accounts approximately 10% of acute myeloid leukemia cases. Acute promyelocytic leukemias usually appears as a de novo finding. The occurrence of secondary acute promyelocytic leukemias after chemotherapy is rare, and the development of secondary acute promyelocytic leukemias after an non-Hodgkin lymphoma is casuistic. The objective of the study is to describe a case of secondary acute promyelocytic leukemia developed  after non-Hodgkin lymphoma therapy <strong>Clinical case. </strong>Male B, 34 ye

APA, Harvard, Vancouver, ISO, and other styles

14

Kiel, Mark J., Thirunavukkarasu Velusamy, Bryan L. Betz, et al. "Whole-genome sequencing identifies recurrent somatic NOTCH2 mutations in splenic marginal zone lymphoma." Journal of Experimental Medicine 209, no. 9 (2012): 1553–65. http://dx.doi.org/10.1084/jem.20120910.

Full text

Abstract:

Splenic marginal zone lymphoma (SMZL), the most common primary lymphoma of spleen, is poorly understood at the genetic level. In this study, using whole-genome DNA sequencing (WGS) and confirmation by Sanger sequencing, we observed mutations identified in several genes not previously known to be recurrently altered in SMZL. In particular, we identified recurrent somatic gain-of-function mutations in NOTCH2, a gene encoding a protein required for marginal zone B cell development, in 25 of 99 (∼25%) cases of SMZL and in 1 of 19 (∼5%) cases of nonsplenic MZLs. These mutations clustered near the C

APA, Harvard, Vancouver, ISO, and other styles

15

Grønbæk, Kirsten, Jesper Worm, Elisabeth Ralfkiaer, Vibeke Ahrenkiel, Peter Hokland, and Per Guldberg. "ATM mutations are associated with inactivation of theARF-TP53 tumor suppressor pathway in diffuse large B-cell lymphoma." Blood 100, no. 4 (2002): 1430–37. http://dx.doi.org/10.1182/blood-2002-02-0382.

Full text

Abstract:

The ATM serine-threonine kinase plays a central role in the cellular response to DNA damage. Germ-line mutations in theATM gene cause ataxia-telangiectasia (A-T), a multisystem disorder associated with predisposition to lymphoma and acute leukemia. Moreover, somatic ATM mutations have been identified in T-cell prolymphocytic leukemia, mantle cell lymphoma, and B-cell chronic lymphocytic leukemia. In this study, the entire ATMcoding sequence was examined in genomic DNA from 120 lymphoid neoplasms. Novel mutations and mutations implicated in cancer and/or A-T were found in 9 of 45 diffuse large

APA, Harvard, Vancouver, ISO, and other styles

16

Sørensen, Karina Dalsgaard, Leticia Quintanilla-Martinez, Sandra Kunder, Jörg Schmidt, and Finn Skou Pedersen. "Mutation of All Runx (AML1/Core) Sites in the Enhancer of T-Lymphomagenic SL3-3 Murine Leukemia Virus Unmasks a Significant Potential for Myeloid Leukemia Induction and Favors Enhancer Evolution toward Induction of Other Disease Patterns." Journal of Virology 78, no. 23 (2004): 13216–31. http://dx.doi.org/10.1128/jvi.78.23.13216-13231.2004.

Full text

Abstract:

ABSTRACT SL3-3 murine leukemia virus is a potent inducer of T-lymphomas in mice. Using inbred NMRI mice, it was previously reported that a mutant of SL3-3 with all enhancer Runx (AML1/core) sites disrupted by 3-bp mutations (SL3-3dm) induces predominantly non-T-cell tumors with severely extended latency (S. Ethelberg, J. Lovmand, J. Schmidt, A. Luz, and F. S. Pedersen, J. Virol. 71:7273-7280, 1997). By use of three-color flow cytometry and molecular and histopathological analyses, we have now performed a detailed phenotypic characterization of SL3-3- and SL3-3dm-induced tumors in this mouse st

APA, Harvard, Vancouver, ISO, and other styles

17

Gill, Saar, and Jennifer N. Brudno. "CAR T-Cell Therapy in Hematologic Malignancies: Clinical Role, Toxicity, and Unanswered Questions." American Society of Clinical Oncology Educational Book, no. 41 (June 2021): e246-e265. http://dx.doi.org/10.1200/edbk_320085.

Full text

Abstract:

At the time of writing, five anti-CD19 CAR T-cell products are approved by the U.S. Food and Drug Administration for seven different indications in lymphoid malignancies, including B-cell non-Hodgkin lymphoma, pediatric B-cell acute lymphoblastic leukemia, and multiple myeloma. CAR T cells for chronic lymphocytic leukemia, acute myeloid leukemia, and less common malignancies such as T-cell lymphomas and Hodgkin lymphoma are being tested in early-phase clinical trials worldwide. The purpose of this overview is to describe the current landscape of CAR T cells in hematologic malignancies, outline

APA, Harvard, Vancouver, ISO, and other styles

18

Yasumizu, R., H. Hiai, K. Sugiura, et al. "Development of donor-derived thymic lymphomas after allogeneic bone marrow transplantation in AKR/J mice." Journal of Immunology 141, no. 6 (1988): 2181–86. http://dx.doi.org/10.4049/jimmunol.141.6.2181.

Full text

Abstract:

Abstract The transplantation of bone marrow cells from BALB/c (but not C57BL/6 and C3H/HeN) mice was observed to lead to the development of thymic lymphomas (leukemias) in AKR/J mice. Two leukemic cell lines, CAK1.3 and CAK4.4, were established from the primary culture of two thymic lymphoma, and surface phenotypes of these cell lines found to be H-2d and Thy-1.2+, indicating that these lymphoma cells are derived from BALB/c donor bone marrow cells. Further analyses of surface markers revealed that CAK1.3 is L3T4+ Lyt2+ IL2R-, whereas CAK4.4 is L3T4- Lyt2- IL2R+. Both CAK1.3 and CAK4.4 were tr

APA, Harvard, Vancouver, ISO, and other styles

19

Mehta, Kathan Dilipbhai, Sameer A. Parikh, Hong Wang, Rahul Atul Parikh, and Roy E. Smith. "National Epidemiology of Inpatient Venous Thromboembolism in Patients with Hematologic Malignancies in United States from 1993 to 2012." Blood 126, no. 23 (2015): 630. http://dx.doi.org/10.1182/blood.v126.23.630.630.

Full text

Abstract:

Abstract Background: Venous thromboembolism (VTE) is an important cause of morbidity and mortality in patients with hematologic malignancies (HMs). The national burden of inpatient VTE in patients with HMs is not known. Methods: We used the National Inpatient Sample (NIS), one of the largest publicly-available inpatient dataset in United States (U.S.), which represents a 20% stratified random sample of discharges from all hospitals, excluding rehabilitation and long-term acute care hospitals. The NIS is drawn from all States participating in Healthcare Cost and Utilization Project, representin

APA, Harvard, Vancouver, ISO, and other styles

20

Radich, Jerald P., Andrew D. Zelenetz, Wing C. Chan, et al. "NCCN Task Force Report: Molecular Markers in Leukemias and Lymphomas." Journal of the National Comprehensive Cancer Network 7, Suppl_4 (2009): S—1—S—34. http://dx.doi.org/10.6004/jnccn.2009.0077.

Full text

Abstract:

The introduction of targeted therapies has revolutionized treatment and improved outcomes in patients with leukemias and lymphomas. However, many patients experience relapse caused by the persistence of residual malignant cells. Cytogenetic and molecular techniques are increasingly being used to assess and quantify minimal residual disease (MRD). The emergence of advanced technologies has led to the discovery of multiple novel molecular markers that can be used to detect MRD and predict outcome in patients with leukemias and lymphomas. Gene expression signatures that predict clinical outcomes

APA, Harvard, Vancouver, ISO, and other styles

21

Suzuki, Takaharu, Hiroaki Miyoshi, Keisuke Kawamoto, et al. "Splenic B-Cell Lymphoma/Leukemia, Unclassifiable in Japan." Blood 132, Supplement 1 (2018): 5301. http://dx.doi.org/10.1182/blood-2018-99-113239.

Full text

Abstract:

Abstract Introduction Splenic B-cell lymphoma/leukemia, unclassifiable is defined as being unable to be classified as any other B-cell neoplasm infiltrating the spleen (World Health Organization Classification of Tumors of Haematopoietic and Lymphoid Tissue 2017). In splenic B-cell lymphoma/leukemia, unclassifiable, splenic diffuse red pulp small cell lymphoma (SDRPL) and hairy cell leukemia variant (HCL-v) are provisionally defined. The incidence of these diseases is rare. It has been reported that they account for 9% of splenic B-cell lymphomas (Haematologica 2010;95:1122-1129). There are no

APA, Harvard, Vancouver, ISO, and other styles

22

Bollard, Catherine M., and A. John Barrett. "Cytotoxic T lymphocytes for leukemia and lymphoma." Hematology 2014, no. 1 (2014): 565–69. http://dx.doi.org/10.1182/asheducation-2014.1.565.

Full text

Abstract:

Abstract This chapter focuses on the recent advances in adoptive T-cell immunotherapies, not only for patients after hematopoietic stem cell transplantation, but also in the autologous setting using T cells early in the disease process for the treatment of the highest-risk patients with leukemias and lymphomas. The particular emphasis is to highlight the role of T-cell therapies for hematologic malignancies using a non-gene-transfer approach to direct specificity, including the clinical use of T-cell therapies for EBV-associated lymphomas and strategies for targeting nonviral lymphoma- and leu

APA, Harvard, Vancouver, ISO, and other styles

23

Cabeçadas, José, Victor E. Nava, Joao L. Ascensao, and Maria Gomes da Silva. "How to Diagnose and Treat CD5-Positive Lymphomas Involving the Spleen." Current Oncology 28, no. 6 (2021): 4611–33. http://dx.doi.org/10.3390/curroncol28060390.

Full text

Abstract:

Patients with CD5-expressing lymphomas presenting with splenomegaly are frequently diagnosed with chronic lymphocytic leukemia. The most important differential diagnosis is mantle cell lymphoma, both in its classical and leukemic, non-nodal forms, given its prognostic and therapeutic implications. Other small B-cell neoplasms that frequently involve the spleen and occasionally express CD5 include the splenic marginal zone lymphoma, hairy cell leukemia and, rarely, lymphoplasmacytic lymphoma. The frequency of CD5 positivity depends in part on the sensitivity of the detection methods employed. U

APA, Harvard, Vancouver, ISO, and other styles

24

Greer, John P. "Therapy of Peripheral T/NK Neoplasms." Hematology 2006, no. 1 (2006): 331–37. http://dx.doi.org/10.1182/asheducation-2006.1.331.

Full text

Abstract:

AbstractThe mature T/natural killer (NK) lymphoma/leukemias represent 5–15% of all non-Hodgkin lymphoma. These diseases have a geographic variation, with more nodal disease in North America and Europe, including peripheral T cell lymphomas, unspecified, anaplastic large cell lymphoma, and angioimmunoblastic T cell lymphoma; and more extranodal disease in Asia due to Epstein-Barr virus–related nasal NK/T lymphoma and human T-cell leukemia virus (HTLV)-1–associated adult T cell leukemia/lymphoma. The prognosis in most peripheral T/NK neoplasms is poor, with 5-year survival less than 30%. Progres

APA, Harvard, Vancouver, ISO, and other styles

25

Vasquez Cervera, Bersayk Saykber, Arkin Bryan Villacis Franco, Jorge Lujan Pinzón, Heidy Marsiglia Armella, and Irina Suley Tirado Perez. "Leucemia de Burkitt, forma de presentación y sobrevida. Reporte de dos casos y revisión de literatura." Revista Colombiana de Hematología y Oncología 12, no. 1 (2025): 184–94. https://doi.org/10.51643/22562915.706.

Full text

Abstract:

Introduction: Burkitt leukemia is a rare entity, also called Burkitt acute lymphoblastic leukemia (B-ALL), and is considered a variant of Burkitt lymphoma/leukemia (B-ALL). It has characteristics similar to acute lymphoblastic leukemia, the most common cancer in children, which is why it should be taken into account in clinical practice. The objective of this article is to present two clinical cases, a rare entity that represents approximately 2% of acute lymphoblastic leukemias in pediatrics. Clinical cases: Two cases of Burkitt leukemia with typical characteristics are presented., with abdom

APA, Harvard, Vancouver, ISO, and other styles

26

Mitchell, J. M., K. R. Meehan, J. Kong, and K. A. Schulman. "Access to bone marrow transplantation for leukemia and lymphoma: the role of sociodemographic factors." Journal of Clinical Oncology 15, no. 7 (1997): 2644–51. http://dx.doi.org/10.1200/jco.1997.15.7.2644.

Full text

Abstract:

PURPOSE Use of bone marrow transplantation (BMT), a complex, costly treatment for many forms of cancers, has increased significantly in recent years. The increasingly competitive health care marketplace raises concerns about patient access to costly medical procedures such as BMT. We attempted to evaluate patient access to BMT for the treatment of leukemias and lymphomas. METHODS We analyzed inpatient hospital discharge data from four states (California, Maryland, Massachusetts, and New York) for 2 years (1988 and 1991) to examine whether the use of BMT for patients with either leukemia or lym

APA, Harvard, Vancouver, ISO, and other styles

27

Tang, Yongmin, Li Guo, Haizhong Zhang, et al. "Reactivity of a Novel Antibody ZCH-2B8a on Normal and Malignant Hematopoietic Cells." Blood 106, no. 11 (2005): 4488. http://dx.doi.org/10.1182/blood.v106.11.4488.4488.

Full text

Abstract:

Abstract Zhejiang Children’s Hospital (ZCH)-2B8a antibody was recently generated in our laboratory using leukemia cell line KG1a as immunogen. This antibody was submitted to the 8th International Workshop and Conference on Human Leukocyte Differentiation Antigens (HLDA8) and the results showed that the antibody recognized an unknown molecule on the surface of some blood cells. In this study, the reactivity of the antibody on normal and malignant hematopoietic cells was investigated and its diagnostic and therapeutic significances were explored. Materials and Methods 3 specimens each of normal

APA, Harvard, Vancouver, ISO, and other styles

28

Conde-Sterling, Daniel A., Nadine S. I. Aguilera, Meenakshi A. Nandedkar, and Susan L. Abbondanzo. "Immunoperoxidase Detection of CD10 in PrecursorT-Lymphoblastic Lymphoma/Leukemia." Archives of Pathology & Laboratory Medicine 124, no. 5 (2000): 704–8. http://dx.doi.org/10.5858/2000-124-0704-idocip.

Full text

Abstract:

Abstract Context.—CD10 was originally reported in non–T-cell lymphoblastic lymphomas/leukemias. It has since been identified, however, in a minority of cases of T-lympho-blastic lymphoma/leukemia and other hematopoietic and nonhematopoietic entities. The usual method for the detection of CD10 previously required fresh tissue. A new antibody for CD10 (56C6) in paraffin embedded tissue sections, however, has recently become available. Objective.—To study the expression of CD10 in paraffin sections of T-lymphoblastic lymphoma/leukemia using monoclonal antibody 56C6. Design.—Twenty-four cases of T

APA, Harvard, Vancouver, ISO, and other styles

29

Steussy, Bryan, Jacqueline Lekostaj, Qining Qian, et al. "Leukemic Transdifferentiation of Follicular Lymphoma Into an Acute Histiocytic Leukemia in a 52-Year-Old Caucasian Woman." Laboratory Medicine 47, no. 2 (2016): 155–57. http://dx.doi.org/10.1093/labmed/lmw011.

Full text

Abstract:

ABSTRACT We report an instructive case of acute myeloid leukemia with histiocytic differentiation (acute histiocytic leukemia) arising in a patient, a 52-year-old woman with a history of follicular lymphoma. The results of genetic studies proved a clonal relationship between the lymphoma and the leukemic cells. To our knowledge, this is the first report of leukemic transdifferentiation of follicular lymphoma into modified base 5-methylcytosine (M5c)–like acute histiocytic leukemia and the first reported karyotype on a transdifferentiated neoplasm.

APA, Harvard, Vancouver, ISO, and other styles

30

Burnett, R. C., W. Vernau, J. F. Modiano, C. S. Olver, P. F. Moore, and A. C. Avery. "Diagnosis of Canine Lymphoid Neoplasia Using Clonal Rearrangements of Antigen Receptor Genes." Veterinary Pathology 40, no. 1 (2003): 32–41. http://dx.doi.org/10.1354/vp.40-1-32.

Full text

Abstract:

Although the diagnosis of canine leukemia and lymphoma in advanced stages is usually uncomplicated, some presentations of the disease can be a diagnostic challenge. In certain situations, lymphoma and leukemia can be difficult to distinguish from a benign reactive proliferation of lymphocytes. Because clonality is the hallmark of malignancy, we have developed an assay that uses the polymerase chain reaction to amplify the variable regions of immunoglobulin genes and T-cell receptor genes to detect the presence of a clonal lymphocyte population. The assay detected clonally rearranged antigen re

APA, Harvard, Vancouver, ISO, and other styles

31

Fricke, William. "CD11b Is Useful in the Diagnosis of Chronic Lymphocytic Leukemia/Prolymphocytic Leukemia, Mixed Chronic Lymphocytic Leukemia, and Prolymphocytic Leukemia." Blood 104, no. 11 (2004): 4806. http://dx.doi.org/10.1182/blood.v104.11.4806.4806.

Full text

Abstract:

Abstract CD11b is well known as an integrin, Mac-1, is often complexed with CD18, and is found on monocytes, granulocytes, and natural killer cells. It also serves as a receptor for iC3b. However, its occurrence in B cell chronic lymphoproliferative disorders is not generally recognized and has not been fully evaluated. To address this issue, a series of B cell leukemias and lymphomas referred for primary diagnosis was evaluated for the presence of CD11b. The purpose was to determine the frequency of its expression on these tumors and to evaluate its diagnostic value. Consecutive cases referre

APA, Harvard, Vancouver, ISO, and other styles

32

Lança, Telma, Daniel V. Correia, Catarina F. Moita та ін. "The MHC class Ib protein ULBP1 is a nonredundant determinant of leukemia/lymphoma susceptibility to γδ T-cell cytotoxicity". Blood 115, № 12 (2010): 2407–11. http://dx.doi.org/10.1182/blood-2009-08-237123.

Full text

Abstract:

Abstract On the path to successful immunotherapy of hematopoietic tumors, γδ T cells offer great promise because of their human leukocyte antigen (HLA)–unrestricted targeting of a wide variety of leukemias/lymphomas. However, the molecular mechanisms underlying lymphoma recognition by γδ T cells remain unclear. Here we show that the expression levels of UL16-binding protein 1 (ULBP1) determine lymphoma susceptibility to γδ T cell–mediated cytolysis. Consistent with this, blockade of NKG2D, the receptor for ULBP1 expressed on all Vγ9+ T cells, significantly inhibits lymphoma cell killing. Speci

APA, Harvard, Vancouver, ISO, and other styles

33

Greenwald, Rebecca J., Joseph R. Tumang, Anupama Sinha та ін. "Eμ-BRD2 transgenic mice develop B-cell lymphoma and leukemia". Blood 103, № 4 (2004): 1475–84. http://dx.doi.org/10.1182/blood-2003-06-2116.

Full text

Abstract:

Abstract Transgenic mice with lymphoid-restricted overexpression of the double bromodomain protein bromodomain-containing 2 (Brd2) develop splenic B-cell lymphoma and, upon transplantation, B-cell leukemia with leukemic infiltrates in liver and lung. Brd2 is a nuclear-localized transcription factor kinase that is most closely related to TATA box binding protein–associated factor, 250 kDa (TAFII250) and the Drosophila developmental protein female sterile homeotic. Constitutive expression of BRD2 in the lymphoid compartment increases cyclin A transcription, “priming” transgenic B cells for proli

APA, Harvard, Vancouver, ISO, and other styles

34

Samiee, Fatemeh, Reza Mohammadi, Sadegh Shirian, et al. "Spectrum of lymphoma subtypes based on the latest World Health Organization classification in southern Iran from 2000 to 2011." Future Oncology 17, no. 34 (2021): 4733–44. http://dx.doi.org/10.2217/fon-2020-0534.

Full text

Abstract:

Background: Lymphoma, both Hodgkin and non-Hodgkin, is one of the most common malignancies, with a distinct subtype distribution throughout the world. Methods: A total of 453 lymphoma cases, identified retrospectively from January 2000 to October 2011, were studied to identify the subtype distribution of lymphoma in our center, located in southern Iran, according to the latest WHO classification. Results: The most common sites of involvement of all lymphomas were extranodal (59.16%). The highest frequency of extranodal sites in all lymphoid neoplasms were associated with diffuse large B-cell l

APA, Harvard, Vancouver, ISO, and other styles

35

Schwarzinger, Ilse, Markus Exner, Harald Esterbauer, et al. "Microvessel Endothelial Cells of Hematological Malignancies Harbor Disease Specific Genetic Aberrations." Blood 104, no. 11 (2004): 544. http://dx.doi.org/10.1182/blood.v104.11.544.544.

Full text

Abstract:

Abstract The growth of most tumors depends on the formation of new blood vessels. In contrast to genetically unstable tumor cells, endothelial cells of tumor vessels are believed to be normal diploid cells that do not acquire mutations. We have recently observed that microvessel endothelial cells of patients with B-cell lymphomas carry lymphoma specific aberrations (NEJM351:250–9, 2004). The aim of this study was to determine whether hematological malignancies other than B-cell lymphomas also carry disease specific genetic aberrations. Using a combined immunohistochemical and fluorescence in s

APA, Harvard, Vancouver, ISO, and other styles

36

Burke, Jerome S. "Lymphoproliferative Disorders of the Gastrointestinal Tract: A Review and Pragmatic Guide to Diagnosis." Archives of Pathology & Laboratory Medicine 135, no. 10 (2011): 1283–97. http://dx.doi.org/10.5858/arpa.2011-0145-ra.

Full text

Abstract:

Context.—The gastrointestinal tract is the most common site of extranodal lymphomas. Although all histologic categories of malignant lymphoma develop in the gastrointestinal tract, large B-cell lymphomas predominate, followed by extranodal marginal zone lymphomas of mucosa-associated lymphoid tissue (MALT) type; the latter is especially prevalent in stomach. The acceptance of extranodal marginal zone lymphoma of MALT type as a clinicopathologic entity has reduced the number of cases that formerly were interpreted as florid lymphoid hyperplasia (“pseudolymphoma”). Nonetheless, the distinction o

APA, Harvard, Vancouver, ISO, and other styles

37

Takahashi, K., Y. Ohtsuki, H. Sonobe, et al. "S-100 beta positive T cell leukemia." Blood 71, no. 5 (1988): 1299–303. http://dx.doi.org/10.1182/blood.v71.5.1299.1299.

Full text

Abstract:

Abstract We reported a peculiar case with T cell leukemia. The patient was a 34- year-old woman showing extensive splenomegaly and marked leukemic cell proliferation and running a rapid fatal clinical course. The leukemic cells were morphologically ordinary lymphocytes showing suppressor/cytotoxic(s/c) T cell phenotypes and containing S-100b protein. Southern blot analysis revealed rearrangement of the beta chain genes of the T cell receptor (TcR) of the leukemic cells. Because these phenotypic and morphologic features were identical with those of S-100 beta+T lymphocytes (S-100 beta +TL) in n

APA, Harvard, Vancouver, ISO, and other styles

38

Takahashi, K., Y. Ohtsuki, H. Sonobe, et al. "S-100 beta positive T cell leukemia." Blood 71, no. 5 (1988): 1299–303. http://dx.doi.org/10.1182/blood.v71.5.1299.bloodjournal7151299.

Full text

Abstract:

We reported a peculiar case with T cell leukemia. The patient was a 34- year-old woman showing extensive splenomegaly and marked leukemic cell proliferation and running a rapid fatal clinical course. The leukemic cells were morphologically ordinary lymphocytes showing suppressor/cytotoxic(s/c) T cell phenotypes and containing S-100b protein. Southern blot analysis revealed rearrangement of the beta chain genes of the T cell receptor (TcR) of the leukemic cells. Because these phenotypic and morphologic features were identical with those of S-100 beta+T lymphocytes (S-100 beta +TL) in normal hum

APA, Harvard, Vancouver, ISO, and other styles

39

Anandani, Garima M., Prabhu Manivannan, Sree Rekha J, Rakhee Kar, and Debdatta Basu. "Patterns of bone marrow infiltration in lymphomas- A retrospective descriptive analysis from a tertiary care centre in Southern India." IP Journal of Diagnostic Pathology and Oncology 7, no. 4 (2023): 223–28. http://dx.doi.org/10.18231/j.jdpo.2022.053.

Full text

Abstract:

Bone marrow biopsy (BMB) examination is the gold standard for staging of lymphoma which is interpreted along with other clinical, laboratory and radiological investigations. This study aimed to evaluate the various patterns of BMB infiltration by lymphomas which include Hodgkin and Non Hodgkin lymphoma and the usefulness of BMB compared to bone marrow aspiration (BMA). : In a period of three years, there were 212 cases which showed lymphoma infiltration in bone marrow. We assessed the peripheral blood smear (PBS), BMA and BMB slides and concordance between each was evaluated. BMB slides were a

APA, Harvard, Vancouver, ISO, and other styles

40

Li, Yang, Chen Jia, Ting Sun, Renchi Yang, and Lei Zhang. "The Relationship between Telomere Length and Epigenetic Aging with Hematologic Diseases Risk: A Multivariable Mendelian Randomisation Study." Blood 142, Supplement 1 (2023): 1316. http://dx.doi.org/10.1182/blood-2023-173594.

Full text

Abstract:

Introduction: Aging is a complex phenomenon that involves multifaceted changes, including significant alterations in telomere length and epigenetic aging. When aging affects the hematopoietic system, it leads to a gradual increase in mutations in hematopoietic stem cells, making individuals more susceptible to the development of hematologic diseases. However, due to the limitations of observational studies, such as potential confounding factors and reverse causality, the precise causal direction and magnitude of the relationship between telomere length, epigenetic aging, and the incidence of h

APA, Harvard, Vancouver, ISO, and other styles

41

Campbell, Neil, Joseph J. Kramer, Katherine Piso, et al. "The Role of ETV6/TEL in Hematopoiesis and Lymphoid Neoplasia." Blood 114, no. 22 (2009): 972. http://dx.doi.org/10.1182/blood.v114.22.972.972.

Full text

Abstract:

Abstract Abstract 972 The transcriptional repressor TEL (Translocation Ets Leukemia) also known as ETV6 (Ets variant gene 6) located on human chromosome 12 is essential for hematopoietic stem cell (HSC) maintenance. Abnormalities involving TEL on the short arm of chromosome 12 including deletions and translocations are common in a surprisingly wide spectrum of hematological and non-hematological malignancies. Genome-wide analysis of leukemic samples revealed the loss of TEL expression and loss of heterozygousity (LOH) in more than half of B-cell ALL patients. We have previously reported on the

APA, Harvard, Vancouver, ISO, and other styles

42

Shi, Bo, Hsin-Ling Hsu, Andy M. Evens, Leo I. Gordon, and Ronald B. Gartenhaus. "Expression of the candidate MCT-1 oncogene in B- and T-cell lymphoid malignancies." Blood 102, no. 1 (2003): 297–302. http://dx.doi.org/10.1182/blood-2002-11-3486.

Full text

Abstract:

Abstract Our laboratory has recently discovered a novel candidate oncogene, MCT-1, amplified in human T-cell lymphoma and mapped to chromosome Xq22-24. This region is amplified in a subset of primary B-cell non-Hodgkin lymphoma (NHL), suggesting that increased copy number of a gene(s) located in this region confers a growth advantage to some primary human lymphomas. We examined a diverse panel of lymphoid malignancies for the expression of MCT-1. We demonstrated that there are significantly increased levels of MCT-1 protein in a panel of T-cell lymphoid cell lines and in non-Hodgkin lymphoma c

APA, Harvard, Vancouver, ISO, and other styles

43

Shi, Yang, and Endi Wang. "Hepatosplenic T-Cell Lymphoma: A Clinicopathologic Review With an Emphasis on Diagnostic Differentiation From Other T-Cell/Natural Killer–Cell Neoplasms." Archives of Pathology & Laboratory Medicine 139, no. 9 (2015): 1173–80. http://dx.doi.org/10.5858/arpa.2014-0079-rs.

Full text

Abstract:

Hepatosplenic T-cell lymphoma is a rare, aggressive T-cell lymphoma, characterized by hepatosplenic sinusoidal infiltration of monotonous, medium-sized, nonactivated cytotoxic T cells, usually of γ/δ T-cell receptor type. Hepatosplenic T-cell lymphoma occurs more frequently in immunocompromised patients, especially in those receiving long-term immunosuppressive therapy. Patients usually manifest hepatosplenomegaly without lymphadenopathy. The bone marrow is also involved in two-thirds of cases and is often accompanied by circulating lymphoma cells, which, along with anemia and thrombocytopenia

APA, Harvard, Vancouver, ISO, and other styles

44

Algashaamy, Khaled, Yaohong Tan, Nicolas Mackrides, et al. "Splenic B-Cell Lymphomas with Diffuse Cyclin D1 Protein Expression and Increased Prolymphocytic Cells: A Previously Unrecognized Diagnostic Pitfall." Case Reports in Hematology 2018 (September 27, 2018): 1–9. http://dx.doi.org/10.1155/2018/5761953.

Full text

Abstract:

Prolymphocytic transformation is a concept usually applied in the context of chronic lymphocytic leukemia/small lymphocytic lymphoma to describe the presence of a high percentage of prolymphocytes in peripheral blood (usually more than 55%). Prolymphocytic transformation has also been reported in mantle cell lymphoma (MCL) but only rarely in splenic marginal zone lymphoma (SMZL). We present two splenic B-cell lymphomas presenting in the leukemic phase and with increased prolymphocytes, both classified as SMZL with prolymphocytic transformation. One case clinically simulated B-prolymphocytic le

APA, Harvard, Vancouver, ISO, and other styles

45

Cherepakhin, V., SM Baird, GW Meisenholder, and TJ Kipps. "Common clonal origin of chronic lymphocytic leukemia and high-grade lymphoma of Richter's syndrome." Blood 82, no. 10 (1993): 3141–47. http://dx.doi.org/10.1182/blood.v82.10.3141.3141.

Full text

Abstract:

Abstract Patients with B-cell chronic lymphocytic leukemia (CLL) infrequently may develop high-grade B-cell lymphoma, or Richter's syndrome lymphoma (RS lymphoma). Such lymphomas differ from the original leukemia in both histology and clinical behavior. Studies seeking to define the clonal relationship between the cells of the two malignancies in any one patient have yielded conflicting reports. We examined the clonal relationship between the early and late neoplastic cells of a patient who underwent Richter's transformation. In contrast to the original leukemia cells, the secondary high-grade

APA, Harvard, Vancouver, ISO, and other styles

46

Cherepakhin, V., SM Baird, GW Meisenholder, and TJ Kipps. "Common clonal origin of chronic lymphocytic leukemia and high-grade lymphoma of Richter's syndrome." Blood 82, no. 10 (1993): 3141–47. http://dx.doi.org/10.1182/blood.v82.10.3141.bloodjournal82103141.

Full text

Abstract:

Patients with B-cell chronic lymphocytic leukemia (CLL) infrequently may develop high-grade B-cell lymphoma, or Richter's syndrome lymphoma (RS lymphoma). Such lymphomas differ from the original leukemia in both histology and clinical behavior. Studies seeking to define the clonal relationship between the cells of the two malignancies in any one patient have yielded conflicting reports. We examined the clonal relationship between the early and late neoplastic cells of a patient who underwent Richter's transformation. In contrast to the original leukemia cells, the secondary high-grade lymphoma

APA, Harvard, Vancouver, ISO, and other styles

47

Xiao, Min, Jianfeng Zhou, and Wei Zhang. "Molecular Classification of Small B-Cell Lymphomas Using Digital Multiplexed Gene Expression Applicable to Formalin-Fixed Paraffin-Embedded Tissues." Blood 134, Supplement_1 (2019): 5770. http://dx.doi.org/10.1182/blood-2019-130446.

Full text

Abstract:

Background: Small B-cell lymphomas encompass a group of lymphoid neoplasms with high heterogeneity. However, the lack of relatively specific diagnostic markers for most of these diseases make their diagnosis challenging. Methods: Using NanoString platform, a random forest-based molecular classification model was trained on 203 malignant and 98 non-malignant formalin-fixed paraffin-embedded (FFPE) tissues. Candidate genes were selected from microarray gene expression data of 891 small B-cell lymphomas. All malignant biopsies were derived from individuals diagnosed as a well-defined small B-cell

APA, Harvard, Vancouver, ISO, and other styles

48

Chatterjee, M., M. Barcos, T. Han, XL Liu, Z. Bernstein, and KA Foon. "Shared idiotype expression by chronic lymphocytic leukemia and B-cell lymphoma." Blood 76, no. 9 (1990): 1825–29. http://dx.doi.org/10.1182/blood.v76.9.1825.1825.

Full text

Abstract:

Abstract Antiidiotype (Id) antibodies identify unique determinants within the surface immunoglobulin (Ig) that are present on B-cell tumors. Anti-Ids have been used for diagnosis and therapy of B-cell lymphoma and leukemia. A panel of 29 anti-Id monoclonal antibodies (MoAbs) that recognize shared idiotypes (SIds) on B-cell lymphomas was tested for reactivity with both B-cell leukemias and lymphomas. Ten of 40 (25%) cases of chronic lymphocytic leukemia (CLL) reacted with at least one of the 29 anti-SId MoAbs. Three cases reacted with more than one anti- SId MoAb, but there was no repetitive pa

APA, Harvard, Vancouver, ISO, and other styles

49

Chatterjee, M., M. Barcos, T. Han, XL Liu, Z. Bernstein, and KA Foon. "Shared idiotype expression by chronic lymphocytic leukemia and B-cell lymphoma." Blood 76, no. 9 (1990): 1825–29. http://dx.doi.org/10.1182/blood.v76.9.1825.bloodjournal7691825.

Full text

Abstract:

Antiidiotype (Id) antibodies identify unique determinants within the surface immunoglobulin (Ig) that are present on B-cell tumors. Anti-Ids have been used for diagnosis and therapy of B-cell lymphoma and leukemia. A panel of 29 anti-Id monoclonal antibodies (MoAbs) that recognize shared idiotypes (SIds) on B-cell lymphomas was tested for reactivity with both B-cell leukemias and lymphomas. Ten of 40 (25%) cases of chronic lymphocytic leukemia (CLL) reacted with at least one of the 29 anti-SId MoAbs. Three cases reacted with more than one anti- SId MoAb, but there was no repetitive pattern of

APA, Harvard, Vancouver, ISO, and other styles

50

Rathi, Shweta P., Vinita Pant, and Jay Mehta. "Cyclin D1 expression in Peripheral T-Cell Lymphoma: A report of 2 cases." IP Archives of Cytology and Histopathology Research 6, no. 4 (2021): 279–82. http://dx.doi.org/10.18231/j.achr.2021.060.

Full text

Abstract:

: Peripheral T-cell lymphomas (PTCLs) represent a heterogeneous group of non-Hodgkin's lymphomas (NHL), characterized by poor outcome, accounting approximately for 10%-15% of all non-Hodgkin lymphomas in the western countries, and with a higher prevalence in Asia. Cyclin D1 immunoreactivity is characteristically seen in mantle cell lymphoma. It is also observed in hairy cell leukemia, plasma cell myeloma and a proportion of diffuse large B-cell lymphomas, however its expression in peripheral T-cell lymphoma is rarely recorded. : We report two cases of peripheral T-cell lymphoma not otherwise s

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!